|   In the News

Atlas wraps Arteaus story with $260M royalty sale as Emgality sales inches upward


Six months after Eli Lilly notched a second-runner-up approval for its CGRP migraine drug Emgality, the Atlas-founded biotech that brought it over the proof-of-concept gate five years ago has sold all its royalty interest for $260 million.

Read more.